山楂消脂胶囊对非急性期冠心病痰瘀证患者Hcy及Hs-CRP影响的研究  

Effect of Shanzha Xiaozhi Capsule on Homocysteine and Hypersensitivity-C Reactive Protein in Patients of Non-acute Coronary Heart Disease with Phlegm and Blood Stasis Syndrome

作　　者：赵华云[1] 王文会[1] 陈伟强[1] 罗子幸[1] 余秀兰[1] 贺青军[1] 黄彪[1] 

机构地区：[1]佛山市中医院心血管内科,广东佛山528000

出　　处：《新中医》2011年第10期9-11,共3页New Chinese Medicine

基　　金：广东省科技厅立项课题(编号:2009B080702010);佛山市禅城区科学技术局社会发展计划项目(编号:2009051)

摘　　要：目的:观察山楂消脂胶囊对非急性期冠心病痰瘀证患者同型半胱氨酸(Hcy)、超敏C反应蛋白(Hs-CRP)的影响,以探讨其对动脉粥样硬化斑块稳定性的影响。方法:将符合诊断标准的100例非急性期冠心病痰瘀证患者随机分为2组。对照组50例予基础治疗加口服血脂康胶囊;治疗组50例予基础治疗加口服山楂消脂胶囊。2组均不用他汀类调脂药,疗程12月。观察2组患者急性心血管事件(MACE)发生率,同时,测定治疗前后Hcy、Hs-CRP、痰浊证计分、血瘀证计分以及MACE发生后各指标的变化。结果:MACE发生率治疗组10.00%,对照组14.00%,2组比较,差异无显著性意义(P>0.05)。但治疗组的MACE发生率较对照组有降低的趋势。经治疗后,2组患者的Hs-CRP、Hcy均较治疗前降低,与治疗前比较,差异均有非常显著性意义(P<0.01);但治疗组的Hcy较对照组更进一步降低,差异有非常显著性意义(P<0.01)。MACE发生后,Hs-CRP、Hcy较治疗前明显升高,说明两者与斑块稳定性密切相关。治疗后2组患者血瘀证计分、痰浊证计分均不同程度下降,与治疗前比较,差异均有非常显著性意义(P<0.01),但治疗组下降较对照组明显,差异有非常显著性意义(P<0.01)。结论:山楂消脂胶囊可通过改善冠心病患者的痰浊血瘀状态,抗炎症反应,降低Hcy水平,稳定冠状动脉粥样硬化斑块,减少非急性期冠心病痰瘀证患者MACE的发生。Objective; To investigate the effect of Shanzha Xiaozhi Capsule on homocysteine （Hcy）and hypersensitivity C-reactive protein（Hs-CRP） in patients of non-acute coronary heart disease with phlegm and blood stasis syndrome. Methods： One-hundred qualified patients were randomly divided into two groups, 50 in each group. The control group was given basic treatment and Xuezhikang, the treatment group was given basic treatment and Shanzha Xiaozhi Capsule. All patients were treated for 12 months without use of statins. The occurrence of major adverse cardiovascular events（MACE）, the changes of blood Hs-CRP and Hcy levels, and the scores of blood-stasis syndrome and phlegm syndrome were measured in both groups before and after treatment. Results. The incidence of MACE was 10.00% in the treatment group and 14.00% in the control group, the difference being insignificant between the two groups （P 〉 0.05）. After treatment, the blood levels of Hs-CRP and Hcy were decreased significantly as compared to those before treatment, and the decrease was obvious in the treatment group （P 〈 0.01）. After the occurrence of MACE, the blood levels of Hs-CRP and Hcy were increased obviously, indicating the close relationship of Hs-CRP and Hcy levels with the stability of plaque. The scores of blood-stasis syndrome and phlegm syndrome were decreased significantly in both group after treatment as compared to those before treatment, and the decrease was obvious in the treatment group （P 〈 0.01）. Conclusion; Shanzha Xiaozhi Capsule can stabilize the atherosclerotic plaque of coronary artery, and then reduce the incidence of MACE in non-acute coronary heart disease patients with phlegm and blood stasis syndrome through improving the state of phlegm and blood stasis, relieving inflammatory reaction, and decreasing the high levels of Hs-CRP and Hcy.

关 键 词：冠心病 非急性期 痰瘀证 中医疗法 山楂消脂胶囊 同型半胱氨酸 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]